Zolgensma Provides No Proven Benefit Over Spinraza In SMA, Says German HTA
IQWiG Laments Lack Of Comparative Data
IQWiG, Germany’s health technology appraisal institute, has found that Novartis’s gene therapy Zolgensma offers no additional benefit compared with Biogen’s Spinraza for treating spinal muscular atrophy, while Roche’s Evrysdi offers a hint of benefit in one patient group.
You may also be interested in...
Zolgensma has exceeded the orphan sales threshold in the six months it has been on the market in Germany and the gene therapy must now undergo a full benefit assessment.
The G-BA has explained in more detail the procedures for mandating post-launch evidence generation under new legislation introduced in 2019.
Two orphan drugs, Chiesi’s Proscybi and Insmed’s Arikayce, were rejected for funding on the Scottish National Health Service.